To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Depomed Completes Enrollment for Non-Hormonal Treatment Study in Menopausal Hot Flashes
Read time: Less than a minute
Depomed, Inc. has announced that it has completed enrollment of Breeze 1, the first of two pivotal Phase 3 clinical trials in Depomed's registration program of DM-5689 for the non-hormonal treatment of menopausal hot flashes.
“We are glad that we achieved this milestone today and look forward to the results of both Breeze 1 and Breeze 2 trials in hot flashes expected later this year. We are well on plan in this important execution year for us,” said Carl A. Pelzel, president and chief executive officer of Depomed.
“DM-5689 has the potential to become a significant alternative treatment of hot flashes for the large number of menopausal women in this country. I am glad that we have achieved this milestone in our clinical study today and I would like to convey my thanks to all the Breeze 1 investigators who have made this possible. We look forward to seeing the results later this year,” added Dr. Risa Kagan, of East Bay Physicians Medical Group and Clinical Professor, Dept. Ob/Gyn, UCSF, the lead investigator for the Breeze 1 study.
“We are glad that we achieved this milestone today and look forward to the results of both Breeze 1 and Breeze 2 trials in hot flashes expected later this year. We are well on plan in this important execution year for us,” said Carl A. Pelzel, president and chief executive officer of Depomed.
“DM-5689 has the potential to become a significant alternative treatment of hot flashes for the large number of menopausal women in this country. I am glad that we have achieved this milestone in our clinical study today and I would like to convey my thanks to all the Breeze 1 investigators who have made this possible. We look forward to seeing the results later this year,” added Dr. Risa Kagan, of East Bay Physicians Medical Group and Clinical Professor, Dept. Ob/Gyn, UCSF, the lead investigator for the Breeze 1 study.
